BioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a strong-buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other equities analysts also recently commented on BCRX. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Weiss Ratings cut BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. JPMorgan Chase & Co. boosted their price target on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 30th. Royal Bank Of Canada downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. Finally, Wedbush lowered their price objective on BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.38.

BioCryst Pharmaceuticals Stock Up 0.8%

Shares of BCRX opened at $7.69 on Friday. The company’s fifty day moving average is $8.46 and its 200-day moving average is $8.75. BioCryst Pharmaceuticals has a 12 month low of $6.23 and a 12 month high of $11.22. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -5.42 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative net margin of 37.40% and a negative return on equity of 92.91%. The business had revenue of $180.29 million for the quarter, compared to the consensus estimate of $165.67 million. During the same quarter last year, the firm earned $0.06 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 13.1% on a year-over-year basis. As a group, research analysts predict that BioCryst Pharmaceuticals will post -2.26 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of BCRX. BlackRock Inc. acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at $238,930,000. Jupiter Topco LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter worth $95,268,000. Janus Henderson Group PLC raised its holdings in BioCryst Pharmaceuticals by 20.3% in the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after acquiring an additional 1,504,120 shares during the period. Perceptive Advisors LLC lifted its position in BioCryst Pharmaceuticals by 135.1% during the 1st quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after acquiring an additional 4,271,504 shares during the last quarter. Finally, Aberdeen Group plc lifted its position in BioCryst Pharmaceuticals by 21.8% during the 3rd quarter. Aberdeen Group plc now owns 6,468,726 shares of the biotechnology company’s stock worth $53,884,000 after acquiring an additional 1,157,855 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.